search engines Durasal Generic Name: salicylic acid Dosage Form: topical solution Overview Side Effects Dosage Professional Interactions More User Reviews Support Group Q & A Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. Package Insert Durasal Rx only FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE. DESCRIPTION Durasal is a topical preparation for treatment of common and plantar warts containing 26% salicylic acid in a film-forming vehicle composed of isopropyl alcohol, butyl acetate, polyvinyl butyral, trimethyl pentanyl diisobutyrate and acrylates copolymer. The pharmacologic activity of Durasal is generally attributed to the keratolytic activity of salicylic acid which is incorporated into a film-forming vehicle designed to cover the wart without the need for a bandage. The structural formula of salicylic acid is: CLINICAL PHARMACOLOGY Although the exact mode of action of salicylic acid in the treatment of warts is not known, its activity appears to be associated with its keratolytic action which results in mechanical removal of epidermal cells infected with wart viruses. INDICATIONS AND USAGE Durasal is indicated for the topical treatment and removal of common warts and plantar warts. CONTRAINDICATIONS Durasal should not be used by diabetics or patients with impaired blood circulation. Durasal should not be used on moles, birthmarks, unusual warts with hair growing from them or warts on the face. PRECAUTIONS Durasal is for external use only. Do not permit Durasal to contact eyes or mucous membranes. If contact with eyes or mucous membranes occurs, immediately flush with water for 15 minutes. Durasal should not be allowed to contact normal skin surrounding wart. Treatment should be discontinued if excessive irritation occurs. Durasal is flammable and should be kept away from fire or flame. Keep bottle tightly capped when not in use. ADVERSE REACTIONS A localized irritant reaction may occur if Durasal is applied to the normal skin surrounding the wart. Any irritation may normally be controlled by temporarily discontinuing use and by applying the medication only to the wart site when treatment is resumed. DOSAGE AND ADMINISTRATION Prior to application of Durasal, soak wart in warm water for five minutes. Remove any loosened tissue by gently rubbing with a brush, wash cloth or emery board. Dry thoroughly. Using the brush applicator supplied, apply twice to entire wart surface, allowing the first application to dry before applying the second. Treatment should be once or twice a day and should continue as directed by physician. Be careful not to apply to surrounding skin. Clinically visible improvement will normally occur during the first or second week of therapy. Maximum resolution may be expected after four to six weeks of drug use. HOW SUPPLIED Durasal is supplied in 10ml amber bottles with a brush applicator (NDC 42783-301-10). Store at controlled room temperature, 15 to 30 C (59 to 86 F). Manufactured for: Elorac, Inc. Vernon Hills, IL 60061 U.S. Patent Pending 6/2009 Slideshow Acne Advice: Skin Care Solutions For Both Teens and Adults Alike Durasal (Salicylic Acid, 26%) Wart Remover 10 mL Container Label Principal Display Panel Text: NDC 42783-301-10 Durasal solution, 26% 10 mL FOR TOPICAL USE ONLY NOT FOR USE IN THE EYES Rx only Durasal (Salicylic Acid, 26%) Wart Remover 10 mL Carton Label Principal Display Panel Text: NDC 42783-301-10 Durasal solution, 26% 10 mL FOR TOPICAL USE ONLY NOT FOR USE IN THE EYES Rx only Durasal salicylic acid solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:42783-301 Route of Administration TOPICAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength salicylic acid (salicylic acid) salicylic acid 260 mg in 1 mL Packaging # Item Code Package Description 1 NDC:42783-301-10 1 BOTTLE, WITH APPLICATOR (BOTTLE) in 1 CARTON 1 10 mL in 1 BOTTLE, WITH APPLICATOR Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 08/03/2009 Labeler - Elorac, Inc. (832590009) Registrant - Elorac, Inc. (832590009) Establishment Name Address ID/FEI Operations Harmony Labs 105803274 manufacture Revised: 02/2010 Elorac, Inc. Next Interactions Print this page Add to My Med List More about Durasal (salicylic acid topical) Side Effects Dosage Information Drug Interactions Support Group 0 Reviews Add your own review/rating Drug class: topical acne agents Consumer resources Durasal Topical (Advanced Reading) Professional resources Salicylic Acid (AHFS Monograph) Salicylic Acid Solution (FDA) Other brands: Salacyn , KeralytGel , Virasal , Keralyt Shampoo , ... +10 more Related treatment guides Acne Dermatological Disorders Warts FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx OTC Availability Rx and/or OTC C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Drug Class Topical acne agents Topical keratolytics Related Drugs topical acne agents clindamycin topical , erythromycin topical , tretinoin topical , tetracycline topical , dapsone topical , Finacea topical keratolytics salicylic acid topical , Compound W , Condylox , Duofilm Warts salicylic acid topical , Compound W , Duofilm , silver nitrate topical , Virasal , Wart Remover , More... Dermatological Disorders triamcinolone , clobetasol topical , betamethasone , Temovate , Diprolene , Analpram-HC , Celestone , More... Acne doxycycline , clindamycin topical , erythromycin topical , minocycline , tretinoin topical , tetracycline topical , dapsone topical , More... Durasal Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! you have to be
place of business Durasal looking for
EmoticonEmoticon